Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways

Hiroshi Hongo, Takeo Kosaka, Yoko Suzuki, Shuji Mikami, Junichi Fukada, Mototsugu Oya

研究成果: Article査読

5 被引用数 (Scopus)


Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the post-cabazitaxel setting. PC3 (CBZ-sensitive) and PC3CR cells (CBZ-resistant) were used in this study. We performed in silico drug screening for candidate drugs that could reprogram the gene expression signature of PC3CR cells. The in vivo effect of the drug combination was tested in xenograft mice models. We identified etoposide (VP16) as a promising treatment candidate for CBZ-resistant CRPC. The WST assay revealed that VP16 had a significant antitumor effect on PC3CR cells. PC3CR cells exhibited significantly higher topoisomerase II alpha (TOP2A) expression than PC3 cells. Higher TOP2A expression was a poor prognostic factor in The Cancer Genome Atlas prostate cancer cohort. In the Fred Hutchinson Cancer Research Center dataset, docetaxel-exposed tissues and metastatic tumors had higher TOP2A expression. In addition, VP16 significantly inhibited the growth of tumors generated from both cell lines. Based on these findings, VP16-based chemotherapy may be an optimal treatment for CPRC in the post-CBZ setting.

ジャーナルScientific reports
出版ステータスPublished - 2021 12月

ASJC Scopus subject areas

  • 一般


「Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。